Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK111 in moderate-to-severe plaque psoriasis
NCT05504317Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- May 2020
- Primary completion
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in plaque psoriasis comparing AK111 regimen with Placebo (2 arms). Primary endpoints: Assessment of Safety at Week 20, Half-Life at Week 20 and 3 more. Started May 2020; status: completed.
02
Drugs
gumokimab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05504317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05504317.